The current financial score of ENDRA Life Sciences Inc is 7.15. Its financial status is robust, and its operating efficiency is low.
The current valuation score of ENDRA Life Sciences Inc is 7.39. Its current P/E ratio is -0.76, which is -102.90% below the recent high of 0.02 and -43.45% above the recent low of -1.09.
The current earnings forecast score of ENDRA Life Sciences Inc is 8.00. The average price target is 25.00, with a high of 25.00 and a low of 25.00.
The current price momentum score of ENDRA Life Sciences Inc is 6.05. Currently, the stock price is trading between the resistance level at 7.26 and the support level at 4.68, making it suitable for range-bound swing trading.
The current institutional shareholding score of ENDRA Life Sciences Inc is 3.00. The latest institutional shareholding proportion is 17.60%, representing a quarter-over-quarter increase of 2.82%.
The current risk assessment score of ENDRA Life Sciences Inc is 1.95. The company's beta value is -0.05. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.